April 27, 2020 Kevzara's Covid-19 setback shows need for hard evidence As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
June 07, 2019 Vertex’s second transformation: Duchenne time The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
June 27, 2017 Aveo comeback highlights a transatlantic split Most drugs get the nod in the US before Europe – but there are some cases where the usual trend is reversed.